
    
      PRIMARY OBJECTIVE:

      I. To assess the safety of itacitinib in patients with bronchiolitis obliterans syndrome
      (BOS) after allogeneic hematopoietic cell transplantation (HCT).

      SECONDARY OBJECTIVES:

      I. To assess treatment failure at 3 months and 6 months. II. To assess change in
      symptom-based lung score at 3 months and 6 months. III. To assess change in the St. George
      Respiratory Questionnaire and Study Short Form 36 at 3 months and 6 months.

      IV. To assess change in the Lee chronic graft versus host disease (GVHD) symptom scale at 3
      months and 6 months post-treatment.

      V. To assess change in 6-minute walk test at 3 months and 6 months. VI. To assess
      failure-free survival at 6 months. VII. To assess non-relapse mortality at 6 months. VIII. To
      assess overall survival at 6 months.

      OUTLINE:

      Patents receive itacitinib orally (PO) once daily (QD) for up to 1 year in the absence of
      disease progression or unacceptable toxicity.
    
  